

1. **The Effect of an Oral Probiotic Mixture on Clinical Evolution and the Gut and Skin Microbiome in Patients with Alopecia Areata: A Randomized Clinical Trial**  
Navarro-Belmonte MR, Aguado-García Á, Sánchez-Pellicer P, Núñez-Delegido E, Navarro-Moratalla L, Martínez-Villaescusa M, García-Navarro A, Navarro-López V.  
*Cosmetics*. 2024; 11(4):119. doi: [10.3390/cosmetics11040119](https://doi.org/10.3390/cosmetics11040119)
2. **A Randomized Clinical Trial to Evaluate the Efficacy of an Oral Probiotic in Acne Vulgaris**  
Eguren C, Navarro-Blasco A, Corral-Forteza M, Reolid-Pérez A, Setó-Torrent N, García-Navarro A, Prieto-Merino D, Núñez-Delegido E, Sánchez-Pellicer P, Navarro-López V.  
*Acta Derm Venereol*. 2024; 104:adv33206. doi: [10.2340/actadv.v104.33206](https://doi.org/10.2340/actadv.v104.33206)
3. **Cutaneous T-Cell Lymphoma and Microbiota: Etiopathogenesis and Potential New Therapeutic Targets**  
Rodríguez Baeza D, Bejarano Antonio L, González de Arriba M, Picó-Monllor JA, Cañueto J, Navarro-Lopez V.  
*Dermatol Res Pract*. 2024; 2024:9919225. doi: [10.1155/2024/9919225](https://doi.org/10.1155/2024/9919225)
4. **Rosacea, microbiome and probiotics: the gut-skin axis.**  
Sánchez-Pellicer P, Eguren-Michelena C, García-Gavín J, Llamas-Velasco M, Navarro-Moratalla L, Núñez-Delegido E, Agüera-Santos J, Navarro-López V.  
*Front Microbiol*. 2024; 14:1323644. doi: [10.3389/fmicb.2023.1323644](https://doi.org/10.3389/fmicb.2023.1323644)
5. **Bladder Cancer and Probiotics: What Do We Know So Far?**  
Sánchez-Pellicer P, Boix-Rodríguez C, Hernández-Belmonte A, Encarnación-Castellano C, Mendiola-López A, Núñez-Delegido E, Navarro-Moratalla L, Agüera-Santos J, Navarro-López V, Galán-Llopis JA.  
*Cancers (Basel)*. 2023; 15(23):5551. doi: [10.3390/cancers15235551](https://doi.org/10.3390/cancers15235551)
6. **Influence and Selection of Probiotics on Depressive Disorders in Occupational Health: Scoping Review.**  
Picó-Monllor JA, Sala-Segura E, Tobares RA, Moreno-Ochando A, Hernández-Teruel A, Navarro-Lopez V.  
*Nutrients*. 2023; 15(16):3551. doi: [10.3390/nu15163551](https://doi.org/10.3390/nu15163551)

- 7. Randomized double-blind placebo- controlled clinical trial to evaluate the effect of a mixture of probiotic strains on symptom severity and use of corticosteroids in children and adolescents with atopic dermatitis.**  
Feito-Rodríguez M, Ramírez-Boscà A, Vidal-Asensi S, Fernández-Nieto D, Ros-Cervera G, Alonso-Usero V, Prieto-Merino D, Núñez-Delegido E, Ruzafa-Costas B, Sánchez-Pellicer P, Genovés S, Navarro-López V.  
*Clin Exp Dermatol.* **2023**; 48(5):495-503. doi: [10.1093/ced/llad007](https://doi.org/10.1093/ced/llad007)
- 8. How Our Microbiome Influences the Pathogenesis of Alopecia Areata.**  
Sánchez-Pellicer P, Navarro-Moratalla L, Núñez-Delegido E, Agüera-Santos J, Navarro-López V.  
*Genes (Basel).* **2022**; 13(10):1860. doi: [10.3390/genes13101860](https://doi.org/10.3390/genes13101860)
- 9. Role of microbiome in kidney stone disease.**  
Galán-Llopis JA, Sánchez-Pellicer P, Navarro-López V.  
*Curr Opin Urol.* **2023**; 33(2):84-89. doi: [10.1097/MOU.0000000000001051](https://doi.org/10.1097/MOU.0000000000001051)
- 10. Oral intake of *Kluyveromyces marxianus* B0399 plus *Lactobacillus rhamnosus* CECT 30579 to mitigate symptoms in COVID-19 patients: A randomized open label clinical trial.**  
Navarro-López V, Hernández-Belmonte A, Pérez Soto MI, Ayo-González M, Losa- Rodríguez G, Ros-Sánchez E, Martínez-Gabarrón M, Sánchez-Pellicer P, Agüera- Santos J, Núñez-Delegido E, Ruzafa-Costas B, Picó-Monllor JA, Navarro-Moratalla L.  
*Med Microecol.* **2022**; 14:100061. doi: [10.1016/j.medmic.2022.100061](https://doi.org/10.1016/j.medmic.2022.100061)
- 11. Acne, Microbiome, and Probiotics: The Gut-Skin Axis.**  
Sánchez-Pellicer P, Navarro-Moratalla L, Núñez-Delegido E, Ruzafa-Costas B, Agüera-Santos J, Navarro-López V.  
*Microorganisms.* **2022**; 10(7):1303. doi: [10.3390/microorganisms10071303](https://doi.org/10.3390/microorganisms10071303)
- 12. A Resistome Roadmap: From the Human Body to Pristine Environments.**  
Maestre-Carballea L, Navarro-López V, Martínez-García M.  
*Front Microbiol.* **2022**; 13:858831. doi: [10.3389/fmicb.2022.858831](https://doi.org/10.3389/fmicb.2022.858831)

**13. Gut Microbiota as a Potential Predictive Biomarker in Relapsing-Remitting Multiple Sclerosis.**

Navarro-López V, Méndez-Miralles MÁ, Vela-Yebra R, Frías-Ramos A, Sánchez-Pellicer P, Ruzafa-Costas B, Núñez-Delegido E, Gómez-Gómez H, Chumillas-Lidón S, Picó-Monllor JA, Navarro-Moratalla L.

*Genes (Basel)*. 2022; 13(5):930. doi: [10.3390/genes13050930](https://doi.org/10.3390/genes13050930)

**14. Selection of Probiotics in the Prevention of Respiratory Tract Infections and Their Impact on Occupational Health: Scoping Review.**

Picó-Monllor JA, Ruzafa-Costas B, Núñez-Delegido E, Sánchez-Pellicer P, Peris-Berraco J, Navarro-Lopez V.

*Nutrients*. 2021; 13(12):4419. doi: [10.3390/nu13124419](https://doi.org/10.3390/nu13124419)

**15. Descriptive Study of Gut Microbiota in Infected and Colonized Subjects by *Clostridiodes difficile*.**

Sánchez-Pellicer P, Navarro-López V, González-Tamayo R, Llopis-Ruiz C, Núñez-Delegido E, Ruzafa-Costas B, Navarro-Moratalla L, Agüera-Santos J.

*Microorganisms*. 2021; 9(8):1727.

**16. Probiotics in the Therapeutic Arsenal of Dermatologists.**

Navarro-López V, Núñez-Delegido E, Ruzafa-Costas B, Sánchez-Pellicer P, Agüera-Santos J, Navarro-Moratalla L.

*Microorganisms*. 2021; 9(7):1513. doi: [10.3390/microorganisms9071513](https://doi.org/10.3390/microorganisms9071513)

**17. Study of the Vaginal Microbiota in Healthy Women of Reproductive Age.**

Alonzo Martínez MC, Cazorla E, Cánovas E, Martínez-Blanch JF, Chenoll E, Climent E, Navarro-López V.

*Microorganisms*. 2021; 9(5):1069. doi: [10.3390/microorganisms9051069](https://doi.org/10.3390/microorganisms9051069)

**18. Changes in Gut Microbiota Correlates with Response to Treatment with Probiotics in Patients with Atopic Dermatitis. A Post Hoc Analysis of a Clinical Trial.**

Climent E, Martínez-Blanch JF, Llobregat L, Ruzafa-Costas B, Carrión- Gutiérrez MÁ, Ramírez-Boscá A, Prieto-Merino D, Genovés S, Codoñer FM, Ramón D, Chenoll E, Navarro-López V.

*Microorganisms*. 2021; 9(4):854. doi: [10.3390/microorganisms9040854](https://doi.org/10.3390/microorganisms9040854)

**19. Efficacy and Safety of Oral Administration of a Mixture of Probiotic Strains in Patients with Psoriasis: A Randomized Controlled Clinical Trial.**

Navarro-López V, Martínez-Andrés A, Ramírez-Boscá A, Ruzafa-Costas B, Núñez-Delegido E, Carrión-Gutiérrez MA, Prieto-Merino D, Codoñer-Cortés F, Ramón-Vidal D, Genovés-Martínez S, Chenoll-Cuadros E, Pérez-Orquín JM, Picó-Monllor JA.

*Acta Derm Venereol.* 2019; 99(12):1078-1084. doi: [10.2340/00015555-3305](https://doi.org/10.2340/00015555-3305)

**20. Gut microbial composition in patients with psoriasis.**

Codoñer FM, Ramírez-Bosca A, Climent E, Carrión-Gutierrez M, Guerrero M, Pérez-Orquín JM, Horga de la Parte J, Genovés S, Ramón D, Navarro-López V, Chenoll E.

*Sci Rep.* 2018; 8(1):3812. doi: [10.1038/s41598-018-22125-y](https://doi.org/10.1038/s41598-018-22125-y)

**21. Effect of Oral Administration of a Mixture of Probiotic Strains on SCORAD Index and Use of Topical Steroids in Young Patients With Moderate Atopic Dermatitis: A Randomized Clinical Trial.**

Navarro-López V, Ramírez-Boscá A, Ramón-Vidal D, Ruzafa-Costas B, Genovés-Martínez S, Chenoll-Cuadros E, Carrión-Gutiérrez M, Horga de la Parte J, Prieto-Merino D, Codoñer-Cortés FM.

*JAMA Dermatol.* 2018; 154(1):37-43. doi: [10.1001/jamadermatol.2017.3647](https://doi.org/10.1001/jamadermatol.2017.3647)

**22. Identification of Bacterial DNA in the Peripheral Blood of Patients With Active Psoriasis.**

Ramírez-Boscá A, Navarro-López V, Martínez-Andrés A, Such J, Francés R, Horga de la Parte J, Asín-Llorca M.

*JAMA Dermatol.* 2015; 151(6):670-1. doi: [10.1001/jamadermatol.2014.5585](https://doi.org/10.1001/jamadermatol.2014.5585)